Inside the research

Envista Holdings Corporation

NVST Research profile · latest available data

Price overview

$23.95

▼ -0.12 (-0.5%)

52w hi$30.26
52w lo$18.95
Vol3.25M
As of25 Sep 2026

The Verdict

Hold

Our score -0.06

Short-0.36
Medium+0.07
Long+0.29

computed 2026-09-27

Key fundamentals

Envista Holdings Corporation

Healthcare · Medical Instruments & Supplies

Market cap$3.85B
Enterprise value$4.31B
Trailing P/E41.29x
Forward P/E14.37x
EV / EBITDA10.61x
P / S (ttm)1.35x
Profit margin3.3%
Return on equity3.1%
Revenue growth+7.1%
Earnings growth+111.3%
Debt / equity51.62

Layer Breakdown

LayerRawContribution
Fundamental+0.28
Sector+0.08
Technical-0.14
Earnings+0.00
Sentiment-0.14

macro × 1.00 · 2026-09-27

Business overview

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

United States · envistaco.com

Risk Metrics

Beta vs SPX1.22
Corr SPX0.49
Annual vol39.8%
Annual ret+19.4%
Sharpe0.49
Max DD-33.9%

Window: 504 trading days (504 obs)

Material Events

DateEvent8-K
2026-08-05Earnings Release, Reg FD Disclosure…read
2026-06-03Officer / Director Change, Exhibitsread
2026-05-21Shareholder Vote, Exhibitsread
2026-05-06Earnings Release, Reg FD Disclosure…read
2026-02-05Earnings Release, Reg FD Disclosure…read
2025-10-29Earnings Release, Reg FD Disclosure…read
2025-10-29Reg FD Disclosure, Exhibitsread
2025-09-17Officer / Director Change, Exhibitsread
2025-07-31Earnings Release, Reg FD Disclosure…read
2025-07-16Officer / Director Change, Exhibitsread
2025-06-12Shareholder Vote, Exhibitsread
2025-05-01Earnings Release, Reg FD Disclosure…read

Insider Trades

DateInsiderRoleActionSharesValue
2026-05-25Keel Paul AChief Executive OfficerWithheld for tax12.81K$300.16K
2026-05-19Carruthers WendyGrant9.33K—
2026-05-19TSINGOS CHRISTINE AGrant9.33K—
2026-05-19Jain VivekGrant9.33K—
2026-05-19GALLAHUE KIERANGrant9.33K—
2026-05-19Pierce James AndrewGrant9.33K—
2026-05-19Raskas DanielGrant9.33K—
2026-05-19Huennekens R ScottGrant12.59K—
2026-02-25Hammes Eric D.Chief Financial OfficerWithheld for tax2.04K$60.51K
2026-02-25Hammes Eric D.Chief Financial OfficerGrant16.05K—

Flow & Concentration

Insider 180d net$0
Insider buys / sells0 / 0
Insider biasNeutral
13F holders10
Top-5 share93.9%
HHI2,687 (concentrated)

Top Holders

HolderValueShares
AQR Capital Management$106.02M4.02M
Renaissance Technologies$40.07M1.52M
Fidelity / FMR LLC$34.57M1.31M
Millennium Management$30.22M1.15M
State Street Corp$12.71M12.68M
Norges Bank (Norway sovereign)$9.82M372.50K
Citadel Advisors$3.50M132.94K
Bridgewater Associates$1.10M41.65K
Capital Research / Capital World$32.02K32.00K
T. Rowe Price Group$4.60K174.41K

As of 2026-06-30

SEC Filings

DateFormDoc
2026-08-133view
2026-08-0510-Qview
2026-08-058-Kview
2026-06-038-Kview
2026-05-274view
2026-05-214view
2026-05-214view
2026-05-214view
2026-05-214view
2026-05-214view
2026-05-214view
2026-05-218-Kview
2026-05-214view
2026-05-068-Kview
2026-05-0610-Qview

The Long Run

FY 2019–2025 · 7 years

LineLatestCAGRTrend
Revenue$2.72B+26.2%
Gross profit$1.44B+22.6%
Operating income-$1.04B-35.3%
Net income-$1.12B+2.2%
Cash from ops$336.50M-1.1%

Indices

S&P MidCap 400

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$24.02$24.19$23.77$23.953.25M
Sep 24$23.80$24.13$23.60$24.072.54M
Sep 23$24.12$24.39$23.81$23.822.41M
Sep 22$23.82$24.48$23.56$24.184.04M
Sep 21$23.68$23.68$23.21$23.433.54M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →